US5747504AExpiredUtility

Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors

Assignee: HOECHST AGPriority: Apr 12, 1984Filed: Sep 6, 1996Granted: May 5, 1998
Est. expiryApr 12, 2004(expired)· nominal 20-yr term from priority
A61K 38/556C07K 5/0222
59
PatentIndex Score
17
Cited by
176
References
3
Claims

Abstract

The invention relates to a method of treating cardiac insufficiency by using compounds of the formula I ##STR1## in which n is 1 or 2, R, R 1 , R 2 and R 3 are identical or different and each denote hydrogen or an organic radical and R 4 and R 5 , together with the atoms carrying them, form a mono-, bi- or tri-cyclic heterocyclic ring system. The invention furthermore relates to compounds of the formula I and agents containing these for use in the treatment of the abovementioned disease.

Claims

exact text as granted — not AI-modified
We claim: 
     
       1. A method for treating cardiac insufficiency in a mammal comprising the step of administering to a mammal in recognized need of, and for the purpose of said treatment, an amount of an angiotensin-converting enzyme inhibitor effective for said treatment, said angiotensin-converting enzyme inhibitor having the formula I: ##STR6## in which R is hydrogen, methyl, ethyl or benzyl; or a pharmaceutically acceptable salt thereof. 
     
     
       2. A method of treating cardiac insufficiency in a mammal comprising the step of administering to a mammal in recognized need of, and for the purpose of said treatment, an amount of angiotensin-converting enzyme inhibitor effective for said treatment, said angiotensin-converting enzyme inhibitor being N-(1-S-carboxy-3-phenyl-propyl)-S-alanyl-S-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof. 
     
     
       3. The method according to claim 1, wherein said inhibitor or salt thereof is administered orally or parenterally.

Join the waitlist — get patent alerts

Track US5747504A — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.